The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2019 | Proof-of-concept approach to overcome proteasome inhibitor resistance in myeloma
Dharminder Chauhan, JD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, describes a novel proof-of-concept approach to inhibit the ubiquitin proteasome pathway at the level of ubiquitin receptors and deubiquitylating enzymes, upstream of the 20S-proteasome, with a goal to block tumor growth and overcome proteasome inhibitor resistance in multiple myeloma. This interview was recorded at the International Myeloma Workshop (IMW) 2019, in Boston, MA.
